Pituitary Cancer Market is expected to register significant growth over the forecast period. The market is projected to register a 5.7% CAGR over the forecast period. Pituitary cancers occur in the pituitary gland that is located beyond the nose. Factors such as the rising prevalence of pituitary cancer are expected to drive market growth. Moreover, the increasing research and development expenditure in the field of oncology for the development of innovative drugs to treat cancer is also expected to boost the market growth.
However, the side effects of the treatment and stringent government regulations are expected to hamper the market growth.
Segmentation
The Global Pituitary Cancer Market has been segmented into Cancer Type, Treatment Type, End User, and Region.
Based on cancer type, the global pituitary cancer market has been segmented into adrenocorticotropic hormone-secreting (ACTH) tumor, growth hormone-secreting tumor, prolactin-secreting tumor, and thyroid-stimulating hormone-secreting tumor.
The global pituitary cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and others. The surgery segment is further segmented into endoscopic trans nasal transsphenoidal surgery and craniotomy. The radiation therapy segment is further segmented into stereotactic radiosurgery, external beam radiation, intensity-modulated radiation therapy (IMRT), and proton beam therapy.
The global pituitary cancer market, by end user, has been segmented into hospitals & clinics, specialty clinics, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The pituitary cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European pituitary cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The pituitary cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa pituitary cancer market has been segmented into the Middle East and Africa.
Key Players
Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Mylan N.V. (US), Johnson & Johnson Services, Inc. (US), Onxeo (France), Ipsen Pharmaceuticals (France), Salix Pharmaceuticals, Inc. (US), and Strides Pharma Science Limited (India) are some of the key players operating in the global pituitary cancer market.
Global Pituitary Cancer Market, by Cancer Type
- Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
- Growth Hormone-Secreting Tumor
- Prolactin-Secreting Tumor
- Thyroid-Stimulating Hormone-Secreting Tumor
Global Pituitary Cancer Market, by Treatment Type
- Surgery
- Endoscopic Transnasal Transsphenoidal Surgery
- Craniotomy
- Radiation Therapy
- Stereotactic Radiosurgery
- External beam radiation
- Intensity Modulated Radiation Therapy (IMRT)
- Proton Beam Therapy
- Chemotherapy
- Others
Global Pituitary Cancer Market, by End User
- Hospitals and Clinics
- Specialty Clinics
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization